NCT04765930 is a NA clinical trial of Q-switched nd:YAG laser toning in Hyperpigmentation, sponsored by Cairo University.

Who is sponsoring NCT04765930?

NCT04765930 is sponsored by Cairo University.

What drugs are being tested in NCT04765930?

Interventions in NCT04765930: Q-switched nd:YAG laser toning.

What condition does NCT04765930 study?

NCT04765930 studies Hyperpigmentation, Melasma, PRP, Lasers.

Is NCT04765930 still recruiting?

NCT04765930 is currently status unknown. Last updated 23 February 2021.

Last reviewed 2021-02-23 · How we verify

NCT04765930

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma

Status unknown NA Last updated 23 February 2021

What this trial tests

NA trial testing Q-switched nd:YAG laser toning in Hyperpigmentation in 30 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
15 February 2021

1 March 2021

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	1 October 2019
Primary completion	15 February 2021
Estimated completion	1 March 2021
Sites	1 location across Egypt

Drugs / interventions tested

Q-switched nd:YAG laser toning

Conditions studied

Hyperpigmentation — all drugs for Hyperpigmentation →
Melasma — all drugs for Melasma →
PRP — all drugs for PRP →
Lasers — all drugs for Lasers →

Sponsor

Cairo University

Who can join

Adults 18 to 70, any sex, with Hyperpigmentation or Melasma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Melasma is a common, acquired, esthetically disfiguring hypermelanosis of the face. Melasma is considered a disappointing challenge when treatment options are addressed. Diverse treatment modalities such as retinoic acid, hypo-pigmenting agents like hydroquinone, azelaic acid, and kojic acid, chemical peels, microdermabrasion, and lasers have been tried for the treatment of melasma. There is no universally proven therapy that induces and maintains remission of the condition. Q-switched: Nd YAG laser toning and platelet rich plasma (PRP) are promising treatments for melasma.The aim of this work is evaluate the efficacy and safety of combined PRP and Q-switched: NdYAG laser in the treatment of melasma using clinical assessment, in addition to assessment of Melanin Index and Erythema Index.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hyperpigmentation

Currently open trials in the same condition.

NCT07162623 — Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Oziva Bioactive Gluta Fizzy Effervescent Tablets on · NA · active not recruiting
NCT07067879 — The Effectiveness of a Novel Lip Product Containing Caulerpa Lentillifera Extract for Reducing Lip Hyperpigmentation · NA · recruiting
NCT06349447 — Pilot Study of LED for PIE and PIH · NA · recruiting
NCT07067515 — Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation · Phase 1, PHASE2 · active not recruiting

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04765930 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04765930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing